Metachromatic Leukodystrophy (MLD) Clinical Trial
Official title:
A Global, Multicenter, Single-arm, Matched External Control Study of Intrathecal SHP611 in Subjects With Late Infantile Metachromatic Leukodystrophy
The main aim of the study is to determine if SHP611 given by injection into the spinal fluid that surrounds the brain and spinal cord (intrathecal; IT) prolongs the time for children with Metachromatic Leukodystrophy (MLD) to retain the ability to move from place to place. Other aims of the study are to determine the effects of intrathecal administration of SHP611 on movement and speech functions and to learn how well SHP611 injected in the spinal fluid that surrounds the brain and spinal cord is tolerated. Study participants will receive SHP611 for about 2 years with the possibility of an extended treatment period.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03725670 -
Lentiviral Gene Therapy for MLD
|
N/A | |
| Withdrawn |
NCT05755568 -
A Study to Learn About Metachromatic Leukodystrophy (MLD) in Children in Spain
|
||
| Terminated |
NCT01963650 -
Natural History Study of Children With Metachromatic Leukodystrophy
|
||
| Active, not recruiting |
NCT01887938 -
An Efficacy and Safety Study of HGT-1110 in Participants With Metachromatic Leukodystrophy
|
Phase 1/Phase 2 | |
| Completed |
NCT00418561 -
Metazym for the Treatment of Patients With Late Infantile Metachromatic Leukodystrophy (MLD)
|
Phase 1 | |
| Completed |
NCT01510028 -
Multicenter Study of HGT-1110 Administered Intrathecally in Children With Metachromatic Leukodystrophy (MLD)
|
Phase 1/Phase 2 | |
| Completed |
NCT01043640 -
Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders
|
Phase 2 | |
| Terminated |
NCT01372228 -
Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders
|
Phase 1/Phase 2 |